Parameters evaluated were frequency of mutations, frequency of mutations per codons (12 or 13), types of mutations, gender, age, and geographic region distributions.
We did not found any correlation between D-Loop mutation and gender.
No significant correlations were found between Axis 1 and diagnosis, mutation, age, gender, or PRNP codon 129.
The patient data contains the following items: disease, reference, template, technique, remarks, mutation origin, gender, occurrence, de novo origin, geographic origin, ethnic origin and population.
These results suggested a significant association of EGFR E19/E21 and BRAF mutations with gender.
There were no correlations between LKB1 mutations and gender or age of a patient.
There is an interaction between the phenotypic manifestation on TS and SF of HFE mutations and gender.
The incidence of 'classical' mutations was gender – (9.4% for males vs 22.7% for females; P=0.139) and histology – (11.8% in adenocarcinomas vs 14.3% in non-adenocarcinomas; P=0.752) independent, while it was significantly higher in 'never-smoker' patients compared to 'smokers' (32 vs 2.1%, respectively; P=0.001).
This is the largest study to point out a statistically difference in the prevalence of KRAS mutations between genders in a cohort of brazilian mCRC patients.
No differences in mutation frequencies comparing gender or median age were observed in our patient cohort (Table 4).
